Advertisement Epix presents encouraging obesity drug data - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Epix presents encouraging obesity drug data

Epix Pharmaceuticals has presented good cognitive function results from a phase Ib safety trial of its drug being developed for obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.

The phase Ib trial was designed to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PRX-07034, a 5-HT6 antagonist, administered orally once-daily for 28 days in a population of obese adults. The trial included measures to assess potential effects on cognitive function and obesity.

The human 5-HT6 receptor is found predominantly in the central nervous system with little or no expression in peripheral tissues, which may result in fewer peripheral side effects.

The primary endpoint was safety and tolerability and PRX-07034 was well tolerated up to 600mg once per day. The secondary endpoint was cognitive function. Overall results on cognitive function showed a dose-dependent trend for improvement associated with PRX-07034.

“We are very pleased with the tolerability and pro-cognitive effects observed in this phase Ib clinical trial of PRX-07034,” said Michael Kauffman, CEO, Epix Pharmaceuticals. “These data support plans to initiate further clinical trials to evaluate the efficacy of PRX-07034 in obesity, cognitive impairment associated conditions, or both.”